A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping

Trial Profile

A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Breast cancer; Malignant melanoma
  • Focus Pharmacodynamics; Registrational
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 16 Jun 2016 Results of retrospective evaluation published in a Navidea Biopharmaceuticals media release.
    • 16 Jun 2016 Results of retrospective evaluation of patients from this and another phase III trial (see CT profile 700239905) were presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), according to a Navidea Biopharmaceuticals media release.
    • 25 Mar 2015 According to a Navidea Biopharmaceuticals media release, Data from this study were presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top